Here's an extract from a company announcement just over 2 years ago when they announced the development of the breast cancer test. Easy to forget why we are here since we're now banging on about htert etc.. Wonder how commercialisation early 2021 is coming along?
"Based on its proprietary BARD1 tumour marker platform, the Company now has three BARD1
autoantibody tests in development for ovarian, breast and lung cancers. BARD1 now plans focus its efforts
on the parallel development and commercialization of both its BARD1 Ovarian and new BARD1 Breast
Cancer tests to take advantage of synergies over the next 2 years with market launch of both tests
expected by early 2021. The Company also intends to advance its BARD1-Lung program and to expand
applications for its BARD1 tumour marker platform to early detection of other cancers."
BD1 Price at posting:
2.5¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)